2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goddard, J. Articles by Webb, D. J. Search for Related Content PubMed PubMed Citation Articles by Goddard, J. Articles by Webb, D. J.

Endothelin A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Are Synergistic via an Endothelin B Receptor–Mediated and Nitric Oxide–Dependent Mechanism

Jane Goddard^*, Corine Eckhart^*, Neil R. Johnston^*, Allan D. Cumming^*, Andrew J. Rankin and David J. Webb^*

*Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; and Pfizer Global Research & Development, Sandwich, United Kingdom

Correspondence to Prof. David J. Webb, Clinical Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK. Phone: +44-131-537-2006; Fax: +44-0870-134-0897; E-mail: d.j.webb{at}ed.ac.uk

Animal studies suggest that endothelin A (ETA) receptor antagonism and angiotensin-converting enzyme (ACE) inhibition may be synergistic. This interaction and the role of ETB receptors and endothelial mediators were investigated in terms of systemic and renal effects in humans in two studies. In one study, six subjects received placebo, the ETA receptor antagonist BQ-123 alone, and BQ-123 in combination with the ETB receptor antagonist BQ-788 after pretreatment with the ACE inhibitor enalapril (E) or placebo. In the other, six subjects who were pretreated with E received placebo, BQ-123, and BQ-123 with concomitant inhibition of nitric oxide (NO) synthase or cyclo-oxygenase (COX). Both were randomized, double-blind, crossover studies. Mean arterial pressure was reduced by BQ-123, an effect that was doubled during ACE inhibition (mean area under curve ± SEM; BQ-123, –2.3 ± 1.8%; BQ-123+E, –5.1 ± 1.1%; P < 0.05 versus placebo). BQ-123 increased effective renal blood flow (BQ-123, –0.1 ± 2.4%; BQ-123+E, 10.9 ± 4.2%; P < 0.01 versus BQ-123), reduced effective renal vascular resistance (BQ-123, –1.2 ± 3.1%; BQ-123+E, –12.8 ± 3.0%; P < 0.01 versus placebo and versus BQ-123), and increased urinary sodium excretion markedly (BQ-123, 2.6 ± 12.8%; BQ-123+E, 25.2 ± 12.6%; P < 0.05 versus BQ-123, P < 0.01 versus placebo and versus E) only during ACE inhibition. These effects were abolished by both ETB receptor blockade and NO synthase inhibition, whereas COX inhibition had no effect. In conclusion, the combination of ETA receptor antagonism and ACE inhibition is synergistic via an ETB receptor–mediated, NO-dependent, COX-independent mechanism. The reduction of BP and renal vascular resistance and associated substantial natriuresis make this a potentially attractive therapeutic combination in renal disease.

This article has been cited by other articles:

				N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF]

				N. Dhaun, C. J. Ferro, A. P. Davenport, W. G. Haynes, J. Goddard, and D. J. Webb Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3228 - 3234. [Abstract] [Full Text] [PDF]

				N F Kelland and D J Webb Clinical trials of endothelin antagonists in heart failure: publication is good for the public health Heart, January 1, 2007; 93(1): 2 - 4. [Abstract] [Full Text] [PDF]

				N. F. Kelland and D. J. Webb Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose? Experimental Biology and Medicine, June 1, 2006; 231(6): 696 - 699. [Abstract] [Full Text] [PDF]

				N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff, L. L. Yanes, R. Iliescu, L. A. Fortepiani, and J. P. Granger Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease Am J Physiol Renal Physiol, November 1, 2005; 289(5): F941 - F948. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673